Subgroup analyses, such as evaluating outcomes based on fiber dosage, further underscored the robustness of the finding, he added
This guide outlines key contraindications, medical conditions requiring caution, and situations demanding thorough consultation with your healthcare provider before initiating GLP-1 or dual GIP/GLP-1 receptor agonist therapy
Kidney Int (2014) 85(3):57989
2024 Jul 23;51(1):835
Tajik N, Frech M, Schulz O, Schlter F, Lucas S, Azizov V, Drholz K, Steffen F, Omata Y, Rings A, Bertog M, Rizzo A, Iljazovic A, Basic M, Kleyer A, Culemann S, Krnke G, Luo Y, berla K, Gaipl US, Frey B, Strowig T, Sarter K, Bischoff SC, Wirtz S, Caete JD, Ciccia F, Schett G, Zaiss MM
Cui, and C.D